Aveo Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$120.0M
Doctors Paid
6,117
Transactions
18,498
2024 Total
$112.5M
Payment Breakdown by Category
Research$118.5M (98.7%)
Food & Beverage$343,629 (0.3%)
Consulting$206,843 (0.2%)
Travel$86,053 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $118.5M | 3,656 | 98.7% |
| Food and Beverage | $343,629 | 12,739 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $323,679 | 138 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $236,603 | 93 | 0.2% |
| Consulting Fee | $206,843 | 111 | 0.2% |
| Honoraria | $147,789 | 97 | 0.1% |
| Education | $91,542 | 1,284 | 0.1% |
| Travel and Lodging | $86,053 | 320 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $75,800 | 25 | 0.1% |
| Entertainment | $4,820 | 35 | 0.0% |
Payments by Type
Research
$118.5M
3,656 transactions
General
$1.5M
14,842 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | $115.1M | 8 | 3,396 |
| A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | $1.5M | 7 | 77 |
| TBD - WCT/AVEO | $1.5M | 4 | 158 |
| Phase II Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (FORTUNE) | $135,447 | 0 | 1 |
| Atezolizumab plus Tivozanib in Immunologically Cold Tumor Types (IMMCO-1) | $98,023 | 0 | 4 |
| A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma | $82,484 | 0 | 20 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Amit Mehta, M.d, M.D | Hematology & Oncology | Cary, NC | $154,980 | $0 |
| Dr. Asad Dean, Md, MD | Medical Oncology | Fort Worth, TX | $89,748 | $0 |
| Dr. Deepak Kilari, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $80,885 | $0 |
| Dr. Hardeep Phull, Md, MD | Internal Medicine | Escondido, CA | $76,923 | $0 |
| Randy Sweis | Hematology & Oncology | Chicago, IL | $52,356 | $0 |
| Dr. Dan Zandberg, Md, MD | Hematology & Oncology | Baltimore, MD | $45,651 | $0 |
| Shaalan Beg, Md, MD | Internal Medicine | Boise, ID | $44,425 | $0 |
| Dr. Kevin Cullen, M.d, M.D | Medical Oncology | Baltimore, MD | $33,920 | $0 |
| Alfredo Torres Gonzalez, M.d, M.D | Hematology & Oncology | Port Jefferson Station, NY | $33,411 | $0 |
| Dr. Raghad Abdul-Karim, Md, MD | Internal Medicine | Mcallen, TX | $33,266 | $0 |
| Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD | Medical Oncology | Dallas, TX | $33,095 | $0 |
| Dr. Przemyslaw Twardowski, Md, MD | Internal Medicine | Santa Monica, CA | $27,967 | $0 |
| Dr. Alan Tan, M.d, M.D | Hematology & Oncology | Nashville, TN | $27,270 | $0 |
| Ghazal Jameel | Nurse Practitioner | Tampa, FL | $25,468 | $0 |
| David Gill | Medical Oncology | Murray, UT | $18,828 | $0 |
| Devalingam Mahalingam, M.d, M.D | Internal Medicine | Chicago, IL | $18,242 | $0 |
| Andreas Kaubisch, Md, MD | Medical Oncology | Bronx, NY | $13,465 | $0 |
| Michael Lattanzi | Medical Oncology | Austin, TX | $13,191 | $0 |
| Dr. Arpita Desai, M.d, M.D | Internal Medicine | San Francisco, CA | $11,029 | $0 |
| Rana Mckay, Md, MD | Hematology & Oncology | San Diego, CA | $10,619 | $0 |
| Christine Chung, Md, MD | Medical Oncology | Tampa, FL | $10,307 | $0 |
| Dr. Thomas Abrams, M.d, M.D | Medical Oncology | Boston, MA | $9,644 | $0 |
| Julie Rowe, M.d, M.D | Internal Medicine | Houston, TX | $8,775 | $0 |
| Ulka Vaishampayan, Md, MD | Medical Oncology | Ann Arbor, MI | $7,983 | $0 |
| Pedro Barata, M.d, M.D | Hematology & Oncology | New Orleans, LA | $7,784 | $0 |
About Aveo Pharmaceuticals, Inc.
Aveo Pharmaceuticals, Inc. has made $120.0M in payments to 6,117 healthcare providers, recorded across 18,498 transactions in the CMS Open Payments database. In 2024, the company paid $112.5M. The top product by payment volume is FOTIVDA ($118.4M).
Payments were distributed across 110 medical specialties. The top specialty by payment amount is Hematology & Oncology ($637,565 to 1,581 doctors).
Payment categories include: Food & Beverage ($343,629), Consulting ($206,843), Research ($118.5M), Travel & Lodging ($86,053).
Aveo Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.